ClinicalTrials.gg
Not yet recruitingNCT07827157Updated Sep 18, 2026

Comparison of Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Erector Spinae Plane Block for Acute Pain Management in Patients With Traumatic Rib Fractures

A Phase 2/3 interventional study of Dexmedetomidine with Bupivacaine in ESPB and Dexamethasone with Bupivacaine in ESPB in Rib Fractures, Acute Pain and Thoracic Trauma, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Assiut University · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Traumatic rib fractures cause severe chest wall pain that can impair normal breathing, coughing, and lung function. While systemic opioids are commonly used to treat traumatic pain, their side effects, such as sedation and respiratory depression, can complicate recovery. Regional nerve blocks like the ultrasound-guided erector spinae plane block (ESPB) offer targeted pain relief while minimizing opioid requirements.

The purpose of this clinical trial is to compare the analgesic efficacy and respiratory outcomes of adding dexmedetomidine versus dexamethasone to bupivacaine during an ultrasound-guided ESPB in emergency department patients with acute traumatic rib fractures.

Participants aged 18 to 65 years presenting within 24 hours of rib injury will be randomly assigned to one of two groups:

  • Dexmedetomidine Group: Receives an ultrasound-guided ESPB with bupivacaine plus dexmedetomidine.
  • Dexamethasone Group: Receives an ultrasound-guided ESPB with bupivacaine plus dexamethasone.

The primary outcome is the duration of analgesia, measured as the time to the first request for rescue pain medication. Secondary outcomes include pain scores at rest and during coughing/deep breathing, total 24-hour opioid consumption, diaphragmatic motion evaluated by ultrasound, respiratory recovery, and the incidence of adverse events over a 24-hour follow-up period.

02

Conditions studied

  • Rib Fractures
  • Acute Pain
  • Thoracic Trauma

Keywords

  • Erector spinae plane block
  • ESPB
  • Dexmedetomidine
  • Dexamethasone
  • Bupivacaine
  • Ultrasound-guided regional anesthesia
  • Rib fracture analgesia
  • Diaphragmatic excursion
03

In context

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 92 interventional studies indexed under Rib Fractures.

Browse Rib Fractures studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 to 65 years
  • Both sexes
  • (ASA) physical status I-II
  • Acute traumatic rib fractures confirmed by appropriate imaging
  • Flail-chest patients who are hemodynamically and respiratory stable to undergo erector spinae plane block (ESPB) and reliable assessment
  • Spontaneously breathing patients or patients receiving supplemental oxygen/non-invasive respiratory support without an immediate indication for intubation
  • Ability to report pain using a Numeric Rating Scale (NRS)
  • Presentation within 24 hours of trauma
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate
  • Immediate need for endotracheal intubation or invasive mechanical ventilation prior to randomization or block placement
  • Hemodynamic instability requiring immediate resuscitation or vasopressor support precluding safe regional anesthesia
  • Cardiorespiratory arrest or peri-arrest status
  • Severe associated traumatic brain injury or other injuries preventing reliable clinical evaluation
  • Major associated injury requiring immediate emergency operative or interventional procedures that prevent protocol completion
  • Coagulopathy or any to regional anesthesia
  • Local infection at the anticipated block needle insertion site
  • Known allergy to amide local anesthetics, dexmedetomidine, or dexamethasone
  • Significant bradyarrhythmia, high-grade atrioventricular block, or contraindication to dexmedetomidine
  • Chronic opioid consumption or chronic pain syndromes requiring regular analgesic therapy
  • Prior regional anesthesia performed for the current trauma
  • Inability to cooperate with the procedure or pain evaluation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine Group

    Participants receive an ultrasound-guided erector spinae plane block (ESPB) with bupivacaine plus dexmedetomidine (0.5 mcg/kg) following local skin infiltration with 5 mL of 2% lidocaine.

    Drug: Dexmedetomidine with Bupivacaine in ESPB

  • Active comparator
    Dexamethasone Group

    Participants receive an ultrasound-guided erector spinae plane block (ESPB) with bupivacaine plus dexamethasone (4 mg) following local skin infiltration with 5 mL of 2% lidocaine.

    Drug: Dexamethasone with Bupivacaine in ESPB

Interventions

  • DrugDexmedetomidine with Bupivacaine in ESPB

    Ultrasound-guided thoracic erector spinae plane block (ESPB) administered deep to the erector spinae muscle and superficial to the transverse process (typically T4-T6) using bupivacaine supplemented with dexmedetomidine (0.5 mcg/kg) following local skin infiltration with 5 mL of 2% lidocaine.

  • DrugDexamethasone with Bupivacaine in ESPB

    Ultrasound-guided thoracic erector spinae plane block (ESPB) administered deep to the erector spinae muscle and superficial to the transverse process (typically T4-T6) using bupivacaine supplemented with dexamethasone (4 mg) following local skin infiltration with 5 mL of 2% lidocaine.

06

What researchers measure

Primary outcomes

  1. Time to First Rescue Analgesic Request

    Time (in minutes) from the completion of the ultrasound-guided erector spinae plane block until the patient's first request for rescue analgesia (or when the Numeric Rating Scale score is 4 or greater).

    Time frame: Up to 24 hours post-block

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07827157
Lead sponsor
Assiut University
Responsible party
Mohamed Elsayed Ali Ibraheim (Resident, Assiut University) — Principal investigator
First posted
Sep 18, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion